BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 30105831)

  • 1. Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer.
    Huang W; Su X; Yan W; Kong Z; Wang D; Huang Y; Zhai Q; Zhang X; Wu H; Li Y; Li T; Wan X
    Prostate; 2018 Dec; 78(16):1248-1261. PubMed ID: 30105831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA VIM-AS1 promotes prostate cancer growth and invasion by regulating epithelial-mesenchymal transition.
    Zhang Y; Zhang J; Liang S; Lang G; Liu G; Liu P; Deng X
    J BUON; 2019; 24(5):2090-2098. PubMed ID: 31786880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA TMPO-AS1 promotes lung adenocarcinoma progression and is negatively regulated by miR-383-5p.
    Mu X; Wu H; Liu J; Hu X; Wu H; Chen L; Liu W; Luo S; Zhao Y
    Biomed Pharmacother; 2020 May; 125():109989. PubMed ID: 32062549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells.
    Bai T; Liu Y; Li B
    IUBMB Life; 2019 Oct; 71(10):1537-1551. PubMed ID: 31188543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA SAP30L-AS1 promotes prostate cancer growth through repressing SAP30L.
    Qin X; Zhu W; Lu A; Wang G; Ye X; Weng G
    Gene; 2019 Mar; 690():120-128. PubMed ID: 30599235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA TP73-AS1 predicts the prognosis of bladder cancer patients and functions as a suppressor for bladder cancer by EMT pathway.
    Tuo Z; Zhang J; Xue W
    Biochem Biophys Res Commun; 2018 May; 499(4):875-881. PubMed ID: 29625110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly expressed long non-coding RNA FEZF1-AS1 promotes cells proliferation and metastasis through Notch signaling in prostate cancer.
    Zhu LF; Song LD; Xu Q; Zhan JF
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5122-5132. PubMed ID: 31298365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA SSTR5-AS1 as a Prognostic Marker Promotes Cell Proliferation and Epithelial-to-Mesenchymal Transition in Prostate Cancer.
    Yuan S; Bi J; Zhang Y
    Crit Rev Eukaryot Gene Expr; 2023; 33(2):1-12. PubMed ID: 36734853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.
    Wang J; Cheng G; Li X; Pan Y; Qin C; Yang H; Hua L; Wang Z
    Tumour Biol; 2016 Jul; 37(7):9603-13. PubMed ID: 26797783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA TMPO-AS1 promotes progression of non-small cell lung cancer through regulating its natural antisense transcript TMPO.
    Qin Z; Zheng X; Fang Y
    Biochem Biophys Res Commun; 2019 Aug; 516(2):486-493. PubMed ID: 31230752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA MNX1-AS1 promotes progression of esophageal squamous cell carcinoma by regulating miR-34a/SIRT1 axis.
    Chu J; Li H; Xing Y; Jia J; Sheng J; Yang L; Sun K; Qu Y; Zhang Y; Yin H; Wan J; He F
    Biomed Pharmacother; 2019 Aug; 116():109029. PubMed ID: 31170665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNA HNF1A-AS1 indicates a poor prognosis of colorectal cancer and promotes carcinogenesis via activation of the Wnt/β-catenin signaling pathway.
    Zhang X; Xiong Y; Tang F; Bian Y; Chen Y; Zhang F
    Biomed Pharmacother; 2017 Dec; 96():877-883. PubMed ID: 29145164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SP1-mediated upregulation of lncRNA SNHG4 functions as a ceRNA for miR-377 to facilitate prostate cancer progression through regulation of ZIC5.
    Wang ZY; Duan Y; Wang P
    J Cell Physiol; 2020 Apr; 235(4):3916-3927. PubMed ID: 31608997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway.
    Qiao X; Lv SX; Qiao Y; Li QP; Ye B; Wang CC; Miao L
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8630-8639. PubMed ID: 30575903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Long Non-Coding RNA NNT-AS1 Correlates with Tumor Progression and Poor Prognosis in Osteosarcoma.
    Ye H; Lin J; Yao X; Li Y; Lin X; Lu H
    Cell Physiol Biochem; 2018; 45(5):1904-1914. PubMed ID: 29518771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.
    Mitobe Y; Ikeda K; Sato W; Kodama Y; Naito M; Gotoh N; Miyata K; Kataoka K; Sasaki H; Horie-Inoue K; Inoue S
    Cancer Sci; 2020 Jul; 111(7):2440-2450. PubMed ID: 32437068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression and Clinicopathological Correlation of Long Noncoding RNA TMPO-AS1 in Colorectal Cancer Patients.
    Mohammadrezakhani H; Baradaran B; Shanehbandi D; Asadi M; Hashemzadeh S; Hajiasgharzadeh K; Safaralizadeh R
    J Gastrointest Cancer; 2020 Sep; 51(3):952-956. PubMed ID: 31768869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA TP73-AS1 sponges miR-194 to promote colorectal cancer cell proliferation, migration and invasion via up-regulating TGFα.
    Cai Y; Yan P; Zhang G; Yang W; Wang H; Cheng X
    Cancer Biomark; 2018; 23(1):145-156. PubMed ID: 30010111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA TMPO-AS1 promotes proliferation and migration in bladder cancer.
    He YC; Bi YG; Jiang L
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8740-8746. PubMed ID: 32964962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA TMPO-AS1/miR-126-5p/BRCC3 axis accelerates gastric cancer progression and angiogenesis via activating PI3K/Akt/mTOR pathway.
    Hu Y; Zhang Y; Ding M; Xu R
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1877-1888. PubMed ID: 33295056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.